

Literatura k oddílu I Rosacea

- Anzengruber F, Czernielewski J, Conrad C, et al. Swiss S1 guideline for the treatment of rosacea. *J Eur Acad Dermatol Venereol*. 2017;31:1775–1791.
- Avdulaj A. Intense pulsed light (IPL) for the treatment of vascular and pigmented lesions. *J Cosmet Dermatol*. 2024;23 (Suppl 1):1–6.
- Benáková N, et al. Moderní farmakoterapie v dermatologii. Praha: Maxdorf, 2020. (Updates in Clinical Dermatology).
- Cary JH, Maibach HI, eds. Rosacea. Cham: Springer, 2020 (Updates in Clinical Dermatology).
- Clanner-Engelshofen BM, Bernhard D, Dargatz S, et al. S2k guideline: Rosacea. *J Dtsch Dermatol Ges*. 2022;20:1147–1165.
- Comeau V, Goodman M, Kober MM, Buckley C. Fractionated carbon dioxide laser Resurfacing as an Ideal Treatment Option for Severe Rhinophyma: A Case Report and Discussion. *J Clin Aesthet Dermatol*. 2019;12:24–27.
- Donnelly A. Demodicosis: clinical, dermatoscopic, and microscopic correlation. *J Am Acad Dermatol*. 2013;68(Suppl 1):AB117.
- Draeos ZD, Gold MH, Weiss RA, et al. Efficacy and safety of oxymetazoline cream 1.0% for persistent facial erythema associated with rosacea: Findings from two phase 3, pivotal trials. *J Am Acad Dermatol*. 2018;78:1156–1163.
- Farshchian M, Daveluy S. Rosacea. In StatPearls [online, last update 2023 Aug 8]. Treasure Island: StatPearls Publishing. Dostupné z <https://www.ncbi.nlm.nih.gov/books/NBK557574/>.
- Gade A, Vasile GF, Hohman MH, Rubenstein R. Intense pulsed light (IPL) therapy. In StatPearls [online, last update 2024 Mar 1]. Treasure Island: StatPearls Publishing, 2025. Dostupné z <https://www.ncbi.nlm.nih.gov/books/NBK580525/>.
- Gallo RL, Granstein RD, Kang S, et al. Standard classification and pathophysiology of rosacea: The 2017 update by the National Rosacea Society Expert Committee. *J Am Acad Dermatol*. 2018;78:148–155.
- Ge L, Li Y, Wu Y, et al. Differential diagnosis of rosacea using machine learning and dermoscopy. *Clin Cosmet Investig Dermatol*. 2022;15:1465–1473.
- Geng RSQ, Bourkas AN, Mufti A, Sibbald RG. Rosacea: pathogenesis and therapeutic correlates. *J Cutan Med Surg*. 2024;28: 178–189.
- Glatz M, Hofbauer GF. Phototoxic and photoallergic cutaneous drug reactions. *Chem Immunol Allergy*. 2012;97:167–179.
- Greenbaum SS, Krull EA, Watnick K. Comparison of CO₂ laser and electrosurgery in rhinophyma. *J Am Acad Dermatol*. 1988;18 (2 Pt 1):363–368.
- Har-el G, Shapshay SM, Bohigian RK, et al. Treatment of rhinophyma: 'cold' versus laser techniques. *Arch Otolaryngol Head Neck Surg*. 1993;119:628–631.
- Chen A, Choi J, Balazic E, et al. Review of laser and energy-based devices to treat rosacea in skin of color. *J Cosmet Laser Ther*. 2024;26:43–53.
- Choe J, Barbieri JS. Emerging medical therapies in rosacea: a narrative review. *Dermatol Ther*. 2023;13:2933–2949.
- Johnson SM, Berg A, Barr C. Recognizing rosacea: tips on differential diagnosis. *J Drugs Dermatol*. 2019;18:888–894.
- Kang S, Amagai M, Bruckner AL, et al. Fitzpatrick's Dermatology. 9th ed. New York: McGraw-Hill, 2019.
- Kim M, Kim J, Jeong SW, Jo H, Park HJ. Long-pulsed 1064-nm Nd:YAG laser ameliorates LL-37-induced rosacea-like lesions. *Lasers Med Sci*. 2018;33:393–397.
- Kim SJ, Lee Y, Seo YJ, et al. Comparative efficacy of radiofrequency and pulsed dye laser in the treatment of rosacea. *Dermatol Surg*. 2017;43:204–209.

- Lee JH, Kim M, Bae JM, et al. Efficacy of the long-pulsed 1064-nm neodymium:yttrium-aluminium-garnet laser (LPND) (rejuvenation mode) in the treatment of papulopustular rosacea (PPR): A pilot study of clinical outcomes and patient satisfaction in 30 cases. *J Am Acad Dermatol*. 2015;73:333–336.
- Lonne-Rahm S, Nordlind K, Edström DW, et al. Laser treatment of rosacea: a pathoetiological study. *Arch Dermatol*. 2004;140:1345–1349.
- Mathis J, Ibrahim SF. Erbium-doped Yttrium Aluminium Garnet (Er:YAG) Laser Resurfacing Restores Normal Function and Cosmesis in Patients with Severe Rhinophyma. *J Clin Aesthet Dermatol* 2019;12:28–33.
- Nguyen C, Kuceki G, Birdsall M, et al. Rosacea: practical guidance and challenges for clinical management. *Clin Cosmet Investig Dermatol*. 2024;17:175–190.
- Nguyen L, Dierckxsens C, Kerscher M, et al. Rosacea treatment with 532 nm KTP versus 595 nm pulsed dye laser: a prospective controlled study. *J Cosmet Dermatol*. 2024;23:2443–2449.
- Sadick H, Riedel F, Bran G. Rhinophym bei Rosazea. Was leistet die operative Therapie? [Rhinophyma in rosacea. What does surgery achieve?]. *Hautarzt*. 2011;62:834–841.
- Salem SAM, Abdel Fattah NS, Tantawy SM, et al. Neodymium-yttrium aluminium garnet laser versus pulsed dye laser in erythmato-telangiectatic rosacea: comparison of clinical efficacy and effect on cutaneous substance (P) expression. *J Cosmet Dermatol*. 2013;12:187–194.
- Seo KY, Kang SM, Ha DY, et al. Long-term effects of intense pulsed light treatment on the ocular surface in patients with rosacea-associated meibomian gland dysfunction. *Cont Lens Anterior Eye*. 2018;41:430–435.
- Shergill M, Khaslavsky S, Avraham S, et al. Review of Intense Pulsed Light in ocular rosacea. *J Cutan Med Surg*. 2024;28:370–374.
- Sticchi A, Fiorito F, Kaleci S, et al. Rosacea and treatment with retinoids: a systematic review and meta-analysis. *Ther Adv Chronic Dis*. 2025;16:20406223251339964.
- Sulk M, Seeliger S, Aubert J, et al. Distribution and expression of non-neuronal transient receptor potential (TRPV) ion channels in rosacea. *J Invest Dermatol*. 2012;132:1253–1262.
- Tian R, Jia Y, Xie L, Wen X. Application of a novel intense pulsed light in rosacea-like mice. *Lasers Surg Med*. 2025;57:544–553.
- van Zuuren EJ, Tan J, van der Linden MMD, Schaller M. Rosacea. In Barker J, Griffiths C, Bleiker T, et al. *Rook's Textbook of Dermatology*. 10th ed. Oxford: Wiley-Blackwell, 2024.
- Vergés C, March De Ribot F, Salgado-Boges J, Gonzalez J. Prospective evaluation of intense pulsed light treatment for meibomian gland dysfunction and blepharitis due to ocular rosacea. IPL treatment for ocular rosacea and meibomian gland dysfunction. *Eur J Dermatol*. 2022;32:505–515.
- Wilkin J, Dahl M, Detmar M, et al. Standard grading system for rosacea: report of the National Rosacea Society Expert Committee on the classification and staging of rosacea. *J Am Acad Dermatol*. 2004;50:907–912.
- Wilkin J, Dahl M, Detmar M, et al. Standard classification of rosacea. *J Am Acad Dermatol*. 2002;46:584–587.
- Zhang T, Liu X, Zhang L, Jiang X. Treatment of rosacea with upadacitinib and abrocitinib: case report and review of evidence for Janus kinase inhibition in rosacea. *Front Immunol*. 2024;15:1416004.
- Zouboulis CC, Katsambas AD, Kligman AM. *Pathogenesis and Treatment of Acne and Rosacea*. Berlin: Springer, 2014.

Literatura k oddílu II Periorální dermatitida

- Arjun P, Ashok J, Samson J, et al. A clinical study of periorbital dermatoses. *J Med Sci Clin Res*. 2017;5:149–155.
- Beacham BE, Kurgansky D, Gould WM. Circumoral dermatitis and cheilitis caused by tartar control dentifrices. *J Am Acad Dermatol*. 1990;22:1029–1032.
- Berardi P, Benvenuti S, Genga A, et al. Demonstration of fusobacteria in eruptions of perioral dermatitis using the tape stripping toluidine blue (TSTB) method. *J Eur Acad Dermatol Venereol*. 1994;3:495–499.
- Bradford LG, Montes LF. Perioral dermatitis and *Candida albicans*. *Arch Dermatol*. 1972;105:892–895.
- Bribeche MR, Fedotov VP, Jillella A, et al. Topical praziquantel as a new treatment for perioral dermatitis: results of a randomized vehicle-controlled pilot study. *Clin Exp Dermatol*. 2014;39:448–453.
- Clementson B, Smidt AC. Periorificial dermatitis due to systemic corticosteroids in children: report of two cases. *Pediatr Dermatol*. 2012;29:140–142.
- Del Rosso JQ, Cash K. Topical corticosteroid application and the structural and functional integrity of the epidermal barrier. *J Clin Aesthet Dermatol*. 2013;6:20–27.
- Dirschka T, Szliska C, Jackowski J, et al. Impaired skin barrier and atopic diathesis in perioral dermatitis. *J Dtsch Dermatol Ges*. 2003;1:199–203.
- Dolenc-Voljc M, Pohar M, Lunder T. Density of *Demodex folliculorum* in perioral dermatitis. *Acta Derm Venereol*. 2005;85:211–215.
- Důra M, Lacina L, Kodet O, et al. Lupus miliaris disseminatus faciei. *Čes Slov Dermatol*. 2018;92:181–184.
- Elmas ÖF, Atasoy M, Akdeniz N, et al. A pediatric recalcitrant case of perioral dermatitis successfully treated with topical 0.03% tacrolimus alone. *Dermatol Ther*. 2020;33:e13253.
- Frieden I, Prose N, Fletcher V, et al. Granulomatous perioral dermatitis in children. *Arch Dermatol*. 1989;125:369–373.
- Garrido PMC, Borges-Costa J. Skin disorders in renal transplant recipients: a retrospective study. *An Bras Dermatol*. 2017;92:638–641.
- Goel NS, Burkhart CN, Morrell DS. Pediatric periorificial dermatitis: clinical course and treatment outcomes in 222 patients. *Pediatr Dermatol*. 2015;32:333–336.
- Goss JM, Nord K, Olarte M, et al. Perioral dermatitis in a patient with myasthenia gravis following systemic corticosteroid treatment. *Br J Dermatol*. 2007;156:1215–1218.
- Grashkin VA, Gromov MS. Diagnostic criteria, epidemiology and substantiation of clinicopathogenetic types of perioral dermatitis. *Voen Med Zh*. 2010;331:32–45.
- Guarneri F, Marini H. An unusual case of perioral dermatitis: possible pathogenic role of neurogenic inflammation. *J Eur Acad Dermatol Venereol*. 2007;21:410–412.
- Hafeez ZH. Perioral dermatitis: an update. *Int J Dermatol*. 2003;42:514–517.
- Chiriac A, Chiriac AE, Madke B, et al. Periorificial dermatitis in infants and preschoolers – a narrative review. *Eur J Pediatr*. 2025;184:143.
- Ishiguro N, Maeda A, Suzuki K, et al. Three cases of perioral dermatitis related to fusobacteria treated with β -lactam antibiotics. *J Dermatolog Treat*. 2014;25:507–509.

- Jansen T, Melnik BC, Schadendorf D. Steroid-induced periorificial dermatitis in children: clinical features and response to azelaic acid. *Pediatr Dermatol*. 2010;27:137–142.
- Jansen T. Azelaic acid as a new treatment for perioral dermatitis: results from an open study. *Br J Dermatol*. 2004;151:933–934.
- Jansen T. Perioral dermatitis successfully treated with topical adapalene. *J Eur Acad Dermatol Venereol*. 2002;16:175–177.
- Kang S, Amagai M, Bruckner AL, et al. *Fitzpatrick's Dermatology*. 9th ed. New York: McGraw-Hill Education, 2019.
- Kruglova LS, Rubtsova LA. Periorální dermatitida: moderní metody terapie. *Lékařská abeceda*. 2022;27:41–44.
- Lee SE, Choi Y, Kim SE, et al. Differential effects of topical corticosteroid and calcineurin inhibitor on the epidermal tight junction. *Exp Dermatol*. 2013;22:59–61.
- Lipozenčić J, Hadžavdić SL. Perioral dermatitis. *Clin Dermatol*. 2014;32:125–130.
- Malik R, Quirk CJ. Topical applications and perioral dermatitis. *Australas J Dermatol*. 2000;41:34–38.
- Mokos ZB, Kummer A, Mosler E, et al. Perioral dermatitis – still a therapeutic challenge. *Acta Clin Croat*. 2015;54:179–185.
- Oppel T, Pavicic T, Kamann S, et al. Pimecrolimus cream (1%) efficacy in perioral dermatitis: results of a randomized, double-blind, vehicle-controlled study in 40 patients. *J Eur Acad Dermatol Venereol*. 2007;21:1175–1180.
- Peters P, Drummond C. Perioral dermatitis from high fluoride dentifrice: a case report and review of literature. *Aust Dent J*. 2013;58:371–372.
- Qureshi A, Friedman A. Comorbidities in dermatology: what's real and what's not. *Dermatol Clin*. 2019;37:65–71.
- Safarini OA, Keshavamurthy C, Patel P. Calcineurin inhibitors. In StatPearls [online, last update 2023 Nov 12]. Treasure Island: StatPearls Publishing, 2025. Dostupné z <https://www.ncbi.nlm.nih.gov/books/NBK558995/>.
- Searle T, Ali FR, Al-Niaimi F. Perioral dermatitis: diagnosis, proposed etiologies, and management. *J Cosmet Dermatol*. 2021;20:3839–3848.
- Schaller M, Gonser L, Belge K, et al. Dual anti-inflammatory and anti-parasitic action of topical ivermectin 1% in papulopustular rosacea. *J Eur Acad Dermatol Venereol*. 2017;31:1907–1911.
- Schaller M, Lenders D, Handgretinger G, et al. Topical ivermectin 10 mg/g cream alone or in combination with oral doxycycline for patients with perioral dermatitis (POD): a retrospective case series. *J Dtsch Dermatol Ges*. 2025;53:299–306.
- Schwarz T, Kreiselmaier I, Bieber T, et al. A randomized, double-blind, vehicle-controlled study of 1% pimecrolimus cream in adult patients with perioral dermatitis. *J Am Acad Dermatol*. 2008;59:34–40.
- Schwensen JF, Menne T, Hald M, et al. Allergic perioral contact dermatitis caused by rubber chemicals during dental treatment. *Contact Dermatit*. 2016;74:110–111.
- Singh A, Oakley A, Wallace L. Syringoma. Online. Dostupné z: <https://dermnetnz.org/topics/syringoma>. [citováno 2026-07-08].
- Sutow EJ, Maillet WA, Taylor JC, et al. In vivo galvanic currents of intermittently contacting dental amalgam and other metallic restorations. *Dent Mater*. 2004;20:823–831.
- Štork J. *Dermatovenerologie*. 2. vyd. Praha: Galén, 2013.
- Tempark T, Shwayder TA. Perioral dermatitis: a review of the condition with special attention to treatment options. *Am J Clin Dermatol*. 2014;15:101–113.
- Tolaymat L, Syed HA, Hall MR. Perioral dermatitis. In StatPearls [online, last update 2025 Jul 6]. Treasure Island: StatPearls Publishing, 2026. Dostupné z <https://www.ncbi.nlm.nih.gov/books/NBK525968/>.
- Tran SS, Ungar B, Brunner PM. Treatment of granulomatous perioral dermatitis with 1.5% topical ruxolitinib cream. *JAAD Case Rep*. 2024;47:1–3.
- Weber K, Thurmayr R, Meisinger A. A topical erythromycin preparation and oral tetracycline for the treatment of perioral dermatitis: a placebo-controlled trial. *J Dermatolog Treat*. 1993;4:57–59.

Wollenberg A, Oppel T. Scoring of skin lesions with the perioral dermatitis severity index (PODSI). *Acta Derm Venereol.* 2006;86:251–252.